Buy Now
Consult NowAbout SEM-P (Semaglutide)
SEM-P (semaglutide) is a long-acting injectable GLP-1 receptor agonist indicated for the management of type 2 diabetes mellitus and obesity.
SEM-P activates GLP-1 receptors through multiple complementary pathways to achieve comprehensive glucose homeostasis and metabolic regulation.
Enhances pancreatic β-cell insulin response
Suppresses excessive glucagon release
Acts on hypothalamic satiety centers
SEM-P is available in two strengths, in both pre-filled pen and vial forms.
Up to 70% of people reach the recommended blood sugar target (<7%) after 40 weeks with 2mg dosing added to their existing diabetes medicines.
About 28.4% individuals lost more than 10% of their body weight, with 2 mg dosing.
These improvements help prevent progression to advanced liver disease.
The overall risk reduction was 24%.
These improvements were observed alongside weight loss.
Sem-P is administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. The vial and Pre-filled pen are designed for self-administration and include built-in safety features. Rotate injection sites each week to minimize irritation. You should demonstrate the proper technique during your first appointment with your patient.
Like all medications, GLP-1 treatments can cause side effects. The most common are mild nausea, vomiting, abdominal pain, and decreased appetite which typically improve after the first few weeks.
Treatment begins with Sem-P 0.25mg weekly for 4 weeks to minimize side effects. Dosage is gradually increased (0.5mg, 1mg, up to 2mg) based on your tolerance and weight loss response. You will adjust your patient’s dose every 4 weeks until reaching the optimal therapeutic level.
Sem-P is contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy, breastfeeding, or for patients with severe gastroparesis. Discuss the complete medical history with your patient to ensure Sem-P is safe for them.
Yes, Sem-P may be used for people with prediabetes and obesity to help with weight loss and improve blood sugar control. It works by helping their body use insulin better and reducing appetite. The decision is made based on your patient’s health, weight goals, and blood sugar levels.
[1] Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology [Internet]. 2021 Sep;9(9):563–74.
[2] Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025 Apr 30;392(21).
[3] Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2diabetes. N Engl J Med. 2024 May 24; 390(21):2011-2023. doi:10 1056/NEJMoa2403347.
[4] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016 Nov 10;375(19):1834–44.
[5] Kosiborod MN et al. N Engl J Med 2023;389:1069–84,
[6] Kosiborod MN et al. N Engl J Med 2024;390:1394–407
[7] Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al. Once-Weekly
Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024 Oct 31;391(17):1573–83.
[8] https://www.worldobesity.org/about/about-obesity/obesity-classification
